NO329809B1 - Perorale sammensetninger av levosimendan med kontrollert frigjoring - Google Patents
Perorale sammensetninger av levosimendan med kontrollert frigjoring Download PDFInfo
- Publication number
- NO329809B1 NO329809B1 NO20005313A NO20005313A NO329809B1 NO 329809 B1 NO329809 B1 NO 329809B1 NO 20005313 A NO20005313 A NO 20005313A NO 20005313 A NO20005313 A NO 20005313A NO 329809 B1 NO329809 B1 NO 329809B1
- Authority
- NO
- Norway
- Prior art keywords
- levosimendan
- composition
- release
- drug
- controlled release
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 111
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 title claims description 80
- 229960000692 levosimendan Drugs 0.000 title claims description 80
- 238000013270 controlled release Methods 0.000 title claims description 18
- 229940079593 drug Drugs 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 34
- 239000002207 metabolite Substances 0.000 claims description 33
- 230000036470 plasma concentration Effects 0.000 claims description 22
- 229920000642 polymer Polymers 0.000 claims description 17
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 16
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 16
- 238000004090 dissolution Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 239000000654 additive Substances 0.000 claims description 14
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 13
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 13
- 239000008363 phosphate buffer Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 12
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 12
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 12
- 230000000996 additive effect Effects 0.000 claims description 11
- 239000000783 alginic acid Substances 0.000 claims description 11
- 229920000615 alginic acid Polymers 0.000 claims description 11
- 235000010443 alginic acid Nutrition 0.000 claims description 11
- 229960001126 alginic acid Drugs 0.000 claims description 11
- 150000004781 alginic acids Chemical class 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 9
- -1 fatty acid ester Chemical class 0.000 claims description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 235000019871 vegetable fat Nutrition 0.000 claims description 5
- 210000002429 large intestine Anatomy 0.000 claims description 3
- 238000009472 formulation Methods 0.000 description 36
- GDZXNMWZXLDEKG-MRVPVSSYSA-N OR-1896 Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NC(C)=O)C=C1 GDZXNMWZXLDEKG-MRVPVSSYSA-N 0.000 description 22
- 239000003826 tablet Substances 0.000 description 11
- 235000021355 Stearic acid Nutrition 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 10
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 10
- 239000008117 stearic acid Substances 0.000 description 10
- 239000002775 capsule Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 206010019280 Heart failures Diseases 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 238000013461 design Methods 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 5
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 229920003091 Methocel™ Polymers 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008173 hydrogenated soybean oil Substances 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000013563 matrix tablet Substances 0.000 description 3
- JJNZXLAFIPKXIG-UHFFFAOYSA-N 2-Chlorobenzylidenemalononitrile Chemical compound ClC1=CC=CC=C1C=C(C#N)C#N JJNZXLAFIPKXIG-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 229920003093 Methocel™ K100 LV Polymers 0.000 description 2
- 229920003094 Methocel™ K4M Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 208000018316 severe headache Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920003096 Methocel™ K100M Polymers 0.000 description 1
- 229920003095 Methocel™ K15M Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI980901A FI980901A (fi) | 1998-04-23 | 1998-04-23 | Levosimendaania säädellysti vapauttavia oraalisia koostumuksia |
PCT/FI1999/000329 WO1999055305A2 (en) | 1998-04-23 | 1999-04-23 | Controlled release peroral compositions of levosimendan |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20005313D0 NO20005313D0 (no) | 2000-10-20 |
NO20005313L NO20005313L (no) | 2000-11-21 |
NO329809B1 true NO329809B1 (no) | 2010-12-20 |
Family
ID=8551575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20005313A NO329809B1 (no) | 1998-04-23 | 2000-10-20 | Perorale sammensetninger av levosimendan med kontrollert frigjoring |
Country Status (38)
Country | Link |
---|---|
US (1) | US7045147B1 (cs) |
EP (1) | EP1071397B1 (cs) |
JP (2) | JP4566402B2 (cs) |
KR (1) | KR100960597B1 (cs) |
CN (1) | CN1248691C (cs) |
AR (1) | AR019096A1 (cs) |
AT (1) | ATE258425T1 (cs) |
AU (1) | AU756641B2 (cs) |
BG (1) | BG64839B1 (cs) |
BR (1) | BR9909869A (cs) |
CA (1) | CA2329234C (cs) |
CO (1) | CO5070607A1 (cs) |
CZ (1) | CZ295194B6 (cs) |
DE (1) | DE69914472T2 (cs) |
DK (1) | DK1071397T3 (cs) |
EA (1) | EA002829B1 (cs) |
EE (1) | EE04220B1 (cs) |
ES (1) | ES2215379T3 (cs) |
FI (1) | FI980901A (cs) |
GE (1) | GEP20032906B (cs) |
HK (1) | HK1034032A1 (cs) |
HR (1) | HRP20000704B1 (cs) |
HU (1) | HUP0101458A3 (cs) |
ID (1) | ID27987A (cs) |
IL (2) | IL138951A0 (cs) |
MX (1) | MXPA00010367A (cs) |
NO (1) | NO329809B1 (cs) |
NZ (1) | NZ507453A (cs) |
PL (1) | PL197447B1 (cs) |
PT (1) | PT1071397E (cs) |
RS (1) | RS49962B (cs) |
SI (1) | SI1071397T1 (cs) |
SK (1) | SK285427B6 (cs) |
TR (1) | TR200003102T2 (cs) |
TW (1) | TWI224507B (cs) |
UA (1) | UA68376C2 (cs) |
WO (1) | WO1999055305A2 (cs) |
ZA (1) | ZA200005632B (cs) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI20011465A0 (fi) * | 2001-07-04 | 2001-07-04 | Orion Corp | Pyridatsinonijohdannaisen uusi käyttö |
BRPI0408323A (pt) * | 2003-03-14 | 2006-03-07 | Nirmal Mulye | processo para a preparação de compimidos de liberação prolongada |
FI20070521L (fi) * | 2006-11-10 | 2008-05-11 | Atacama Labs Oy | Rakeita, tabletteja ja rakeistusmenetelmä |
MX337213B (es) | 2008-06-30 | 2016-02-17 | Tocagen Inc | Formulaciones de 5-fluorocitosina y usos de las mismas. |
JP2014172850A (ja) * | 2013-03-07 | 2014-09-22 | Capsugel Belgium Nv | ハードカプセル製剤 |
CN105784895B (zh) * | 2015-10-30 | 2018-05-22 | 成都欣捷高新技术开发有限公司 | 一种用高效液相色谱仪检测左西孟旦中杂质的方法 |
US11969424B2 (en) | 2019-12-16 | 2024-04-30 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ203684A (en) | 1982-04-05 | 1986-06-11 | Merck Sharp & Dohme | Granular formulation for the stabilization of unstable drugs or food supplements |
US4716042A (en) | 1986-06-16 | 1987-12-29 | American Home Products Corporation | Stabilized coated aspirin tablets |
GB8903130D0 (en) | 1989-02-11 | 1989-03-30 | Orion Yhtymae Oy | Substituted pyridazinones |
GB2251615B (en) * | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
US5213811A (en) * | 1991-09-13 | 1993-05-25 | Sterling Drug Inc. | Oral sustained-release drug compositions |
GB2266841A (en) * | 1992-05-06 | 1993-11-17 | Orion Yhtymae Oy | Compounds for use as anti-ischemic medicaments |
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
GB9614098D0 (en) | 1996-07-05 | 1996-09-04 | Orion Yhtymae Oy | Transdermal delivery of levosimendan |
FI973804A (fi) * | 1997-09-26 | 1999-03-27 | Orion Yhtymae Oy | Levosimendaanin oraalisia koostumuksia |
FI974578A (fi) * | 1997-12-19 | 1999-06-20 | Orion Yhtymae Oyj | Menetelmä levosimendaanin antamiseksi |
FI980902A (fi) * | 1998-04-23 | 1999-10-24 | Orion Yhtymae Oyj | Levosimendaanin stabiileja koostumuksia |
-
1998
- 1998-04-23 FI FI980901A patent/FI980901A/fi unknown
-
1999
- 1999-03-26 CO CO99018533A patent/CO5070607A1/es unknown
- 1999-04-09 TW TW088105661A patent/TWI224507B/zh not_active IP Right Cessation
- 1999-04-22 AR ARP990101869A patent/AR019096A1/es active IP Right Grant
- 1999-04-23 SK SK1554-2000A patent/SK285427B6/sk not_active IP Right Cessation
- 1999-04-23 NZ NZ507453A patent/NZ507453A/xx unknown
- 1999-04-23 AU AU35246/99A patent/AU756641B2/en not_active Ceased
- 1999-04-23 IL IL13895199A patent/IL138951A0/xx active IP Right Grant
- 1999-04-23 PT PT99916941T patent/PT1071397E/pt unknown
- 1999-04-23 EP EP99916941A patent/EP1071397B1/en not_active Expired - Lifetime
- 1999-04-23 PL PL344078A patent/PL197447B1/pl not_active IP Right Cessation
- 1999-04-23 TR TR2000/03102T patent/TR200003102T2/xx unknown
- 1999-04-23 CZ CZ20003780A patent/CZ295194B6/cs not_active IP Right Cessation
- 1999-04-23 JP JP2000545505A patent/JP4566402B2/ja not_active Expired - Fee Related
- 1999-04-23 HU HU0101458A patent/HUP0101458A3/hu unknown
- 1999-04-23 RS YUP-639/00A patent/RS49962B/sr unknown
- 1999-04-23 AT AT99916941T patent/ATE258425T1/de not_active IP Right Cessation
- 1999-04-23 ID IDW20002367A patent/ID27987A/id unknown
- 1999-04-23 MX MXPA00010367A patent/MXPA00010367A/es unknown
- 1999-04-23 EE EEP200000617A patent/EE04220B1/xx not_active IP Right Cessation
- 1999-04-23 CA CA002329234A patent/CA2329234C/en not_active Expired - Fee Related
- 1999-04-23 DK DK99916941T patent/DK1071397T3/da active
- 1999-04-23 EA EA200001098A patent/EA002829B1/ru not_active IP Right Cessation
- 1999-04-23 US US09/673,794 patent/US7045147B1/en not_active Expired - Fee Related
- 1999-04-23 SI SI9930536T patent/SI1071397T1/xx unknown
- 1999-04-23 GE GEAP19995639A patent/GEP20032906B/en unknown
- 1999-04-23 WO PCT/FI1999/000329 patent/WO1999055305A2/en not_active Application Discontinuation
- 1999-04-23 ES ES99916941T patent/ES2215379T3/es not_active Expired - Lifetime
- 1999-04-23 BR BR9909869-5A patent/BR9909869A/pt not_active Application Discontinuation
- 1999-04-23 CN CNB998064181A patent/CN1248691C/zh not_active Expired - Fee Related
- 1999-04-23 DE DE69914472T patent/DE69914472T2/de not_active Expired - Lifetime
- 1999-04-23 UA UA2000116616A patent/UA68376C2/uk unknown
- 1999-04-23 KR KR1020007011788A patent/KR100960597B1/ko not_active IP Right Cessation
-
2000
- 2000-10-11 IL IL138951A patent/IL138951A/en not_active IP Right Cessation
- 2000-10-12 ZA ZA200005632A patent/ZA200005632B/en unknown
- 2000-10-19 HR HR20000704A patent/HRP20000704B1/xx not_active IP Right Cessation
- 2000-10-20 NO NO20005313A patent/NO329809B1/no not_active IP Right Cessation
- 2000-11-17 BG BG104959A patent/BG64839B1/bg unknown
-
2001
- 2001-02-14 HK HK01101050A patent/HK1034032A1/xx not_active IP Right Cessation
-
2010
- 2010-01-12 JP JP2010004367A patent/JP2010083900A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210093575A1 (en) | Immediate release formulations and dosage forms of gamma-hydroxybutyrate | |
AU2010352575B2 (en) | Immediate release formulations and dosage forms of gamma-hydroxybutyrate | |
EP1441713B2 (en) | Modified release tamsulosin tablets | |
AU2008207707A1 (en) | Sustained release ranolazine formulations | |
KR20150028367A (ko) | 히드로모르폰 및 날록손을 포함하는 제약 조성물 | |
KR100712032B1 (ko) | 신규한 페노피브레이트 갈레노스 제제의 제조방법, 제조된갈레노스 제제 및 용도 | |
JP2010083900A (ja) | レボシメンダンの制御放出経口用組成物 | |
US20220280500A1 (en) | Pharmaceutical compositions of cabozantinib | |
CN114845704A (zh) | 包含西苯唑啉或其盐的药物制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |